RESEARCH LETTER

Clinical profile and response to treatment of patients with psoriasis seen via teledermatology during the COVID-19 pandemic in the Philippines

To the Editor: Psoriasis is a chronic disease that requires long-term follow-up. The COVID-19 pandemic has prompted us to increase the use of teledermatology (TD) to care for our patients with psoriasis. We conducted a descriptive cross-sectional study of our patients with psoriasis seen via TD during the pandemic, describing their demographic and clinical profile and evaluating their response to treatment.

We reviewed 424 charts of patients with psoriasis seen via TD who had new-onset psoriasis flareup and who had a follow-up at 1 month. The study

Table I. Demographic and clinical profile of patients with psoriasis seen via teledermatology in Rizal Medical Center

| Characteristics                  | Mean (SD) or frequency (%) n = 424 |
|----------------------------------|------------------------------------|
| Age, y                           |                                    |
| 0-18                             | 34 (SD, 13)                        |
| 19-30                            | 144 (34%)                          |
| 31-40                            | 118 (28%)                          |
| 41-50                            | 69 (16%)                           |
| 51-60                            | 39 (9%)                            |
| >60                              | 20 (5%)                            |
| Sex                              |                                    |
| Male                             | 159 (38%)                          |
| Female                           | 265 (63%)                          |
| Type of patient                  |                                    |
| New                              | 221 (52%)                          |
| Returning                        | 203 (48%)                          |
| Method of diagnosis              |                                    |
| Clinical                         | 399 (94%)                          |
| Histologic                       | 25 (6%)                            |
| Disease severity*                |                                    |
| Mild                             | 171 (40%)                          |
| Moderate                         | 216 (51%)                          |
| Severe                           | 27 (9%)                            |
| Subtype by morphology            |                                    |
| Plaque                           | 367 (87%)                          |
| Guttate                          | 31 (7%)                            |
| Erythrodermic                    | 17 (4%)                            |
| Pustular                         | 9 (2%)                             |
| Subtype by location              |                                    |
| Scalp                            | 237 (56%)                          |
| Face                             | 27 (6%)                            |
| Palmoplantar                     | 7 (2%)                             |
| Inverse                          | 7 (2%)                             |
| Genital                          | 3 (1%)                             |
| Nail finding                     |                                    |
| Present                          | 209 (49%)                          |
| Absent                           | 215 (51%)                          |
| Psoriatic arthritis              |                                    |
| Present                          | 77 (18%)                           |
| Absent                           | 347 (82%)                          |
| With cardiovascular comorbidity  | 69 (16%)                            |
| Hypertension                     | 30 (7%)                            |
| Overweight/obesity               | 24 (6%)                            |
| Diabetes/prediabetes             | 14 (3%)                            |
| Dyslipidemia                      | 1 (0.2%)                           |
| With noncardiovascular comorbidity| 2 (0.5%)                       |
| Liver disease                    | 1 (0.2%)                           |
| Kidney disease                   | 1 (0.2%)                           |
| Reported trigger†                |                                    |
| None                             | 127                                |
| Non—lifestyle factor             |                                    |
| Mental stress                    | 195 (46%)                          |
| Changes in weather               | 56 (13%)                           |
| Discontinuation or lack of medication| 44 (10%)                      |
| Infection                        | 43 (10%)                           |
| Trauma                           | 2 (0.5%)                           |
| Lifestyle factor                 |                                    |
| Poor sleep                       | 23 (5%)                            |
| Overeating                       | 6 (1%)                             |
| Smoking                          | 6 (1%)                             |
| Alcohol intake                   | 4 (1%)                             |
| No exercise/sedentary lifestyle  | 1 (0.2%)                           |
| Treatment                        |                                    |
| Monotherapy                      | 191 (45%)                          |
| Topical corticosteroid           | 131 (31%)                          |
| Topical vitamin D analog         | 46 (11%)                           |
| Methotrexate                     | 9 (2%)                             |
| Secukinumab                      | 4 (0.9%)                           |
| Cyclosporine                     | 1 (0.2%)                           |
| Combination therapy              | 233 (55%)                          |
| Topical + methotrexate           | 118 (28%)                          |
| Topical corticosteroid + vitamin D analog | 108 (25%)          |
| Topical + secukinumab            | 4 (0.9%)                           |
| Topical + cyclosporine           | 3 (0.7%)                           |

Table I. Cont’d

*Assessed using psoriasis area severity index and dermatology life quality index.
†Each patient can have more than 1 reported trigger.

© 2022 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
duration was from October 2020 to April 2021. Table I shows the demographic and clinical profile of the cohort. Treatment response was evaluated by comparing the psoriasis area severity index (PASI) and dermatology life quality index (DLQI) at the time of new-onset flareup and at follow-up at 1 month (Table II). Mean PASI and DLQI decreased from the baseline to follow-up. PASI and DLQI reduction was the highest for severe disease, 26% and 18%, respectively. Moderate psoriasis had a 20% and 13% reduction, respectively, whereas mild disease had a 19% and 11% reduction, respectively, in PASI and DLQI.

Our study provides real-world data on the use of TD to care for patients with psoriasis during the pandemic. It is noteworthy that our patients were younger than those of 2 registry-based studies, the study by Ng et al1 before the pandemic and the study by Mahil et al2 during the pandemic, which had a mean age of patient of 44 years (SD, 16 years) and 47.2 years (SD, 15.1 years), respectively. It is possible that younger patients are more adept at using technology than older patients and may explain the greater number of patients aged <40 years in our study. We recommend a study on TD utilization patterns and feedback to help older patients keep abreast of technology.

Forty-six percent of our patients reported mental stress as a trigger of the disease flareup. This may be attributed to the effects of the pandemic, which has restricted mobility, caused the loss of income, and has led to stress, anxiety, and depression.3 We encourage psychosocial support for these patients.

The reduction in PASI and DLQI in our patients across all severity groups suggests that TD is a useful alternative in caring for patients with psoriasis, especially in this pandemic. In our institution, we use hybrid TD because most of our patients do not have a reliable internet connection, which precludes good-quality video conferencing. Hybrid TD allows us to better assess the condition through photographs sent via the Facebook messenger (store-and-forward TD) combined with a telephonic call (real-time interactive TD) to review patients’ clinical history and explain management. We use the Facebook messenger because it is accessible to most patients, including those from resource-poor regions. Similarly, Angeles et al4 reported that most dermatologists in the Philippines use hybrid TD, with the Facebook messenger as the second most commonly used platform.

Limitations of our study include the lack of a control group and long-term follow-up. To validate our findings, we recommend including a cohort of patients with psoriasis seen in-office as a control group and including long-term follow-up assessments in future studies.

**Table II. Psoriasis area severity index and dermatology life quality index at baseline and after 1 month of treatment**

| Disease severity | PASI Mean (SD) | DLQI Mean (SD) |
|------------------|----------------|----------------|
|                  | Baseline | After 1 mo | % decrease | Baseline | After 1 mo | % decrease |
| Mild             | 6.42 (4.52) | 5.17 (4.21) | 19% | 10.94 (7.31) | 9.76 (6.94) | 11% |
| Moderate         | 16.03 (8.37) | 12.85 (7.39) | 20% | 16.59 (7.54) | 14.41 (8.15) | 13% |
| Severe           | 27.2 (12.33) | 20.1 (12.13) | 26% | 18.83 (6.14) | 15.51 (7.89) | 18% |

DLQI, Dermatology life quality index; PASI, psoriasis area severity index.

Patricia Anne Tinio, MD, Jacqueline Michelle Melendres, MD, Czarina P. Chavez, MD, Maicka Keirsten Agon, MD, Arbie Sofia Merilleno, MD, Rogelio Balagat, MD, Lily Lyralin Tumalad, MD, Alma Gay Concepcion Amado, MD, and Francisco Rivera, IV, MD

From the Department of Dermatology, Rizal Medical Center, Pasig Boulevard, Pasig, Philippines.

**Funding sources:** None.

**IRB approval status:** The study protocol was approved by institutional review board of the Rizal Medical Center (protocol code: 2021-D=#021=RP.2.II).

**Key words:** COVID-19; medical dermatology; Philippines; psoriasis; teledermatology; telemedicine.

**Correspondence to:** Czarina P. Chavez, MD, Department of Dermatology, Rizal Medical Center, Pasig Blvd, Pasig, Metro Manila 1600, Philippines.

**E-mail:** chaipineda@gmail.com

**Conflicts of interest**

Dr Tinio has received honoraria as a member of the advisory board and speaker from Novartis, Janssen/J&J, and Zuellig Lilly. Dr Chavez has received fees as a speaker from LeoPharma and Glenmark and a research grant paid to her institution as principal investigator from Glenmark. Dr Balagat has received fees as a speaker from Novartis. Dr
Tumalad has received honoraria as a speaker from Novartis, LeoPharma, and J&J and research funds as principal investigator from Novartis. Drs Melendres, Agon, Merilleno, Amado, and Rivera have no conflicts of interest to declare.

REFERENCES

1. Ng JNC, Guevara BEG, Guillano VP. Demographic and clinical profiles of adult Filipino patients with psoriasis in Davao City: a cross sectional study. J Philipp Dermatological Soc. 2018;27(1):41-63.

2. Mahil SK, Yates M, Yiu ZZN, et al. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol. 2021;35(10):e636-e640. https://doi.org/10.1111/jdv.17450

3. Kuang Y, Shen M, Wang Q, et al. Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: a web-based survey. J Am Acad Dermatol. 2020;83(2):670-672. https://doi.org/10.1016/j.jaad.2020.05.018

4. Angeles C, Chavez C, Lim H, Guevara B, Jamisola L. Impact of the COVID-19 pandemic on dermatology practice in the Philippines: a cross-sectional study. Australas J Dermatol. 2021;62(4):e594-e596. https://doi.org/10.1111/AJD.13714

https://doi.org/10.1016/j.jdin.2022.02.001